Development of Withdrawal Time of Eprinomectin Residue in Ovine Tissues after Subcutaneous Administration

江海洋,丁双阳,刘金凤,赵思俊,何继红,吴聪明,李建成,沈建忠
DOI: https://doi.org/10.3321/j.issn:0366-6964.2009.03.027
2009-01-01
Abstract:In this study,a high performance liquid chromatography method with fluorescence detector(HPLC-FLD) was developed for determination of eprinomectin residue in bovine muscle,liver,kidney,and fat tissues.The tissue samples were extracted with acetonitrile,and cleaned up using basic SPE cartridge.Fortified at levels of 2-100 ng·g-1,mean recoveries were 70.5%-91.2%,with coefficient of variation of 2.3%-11.5%.The limit of detection and limit of quantitation were 1 and 2 ng·g-1,respectively.Eighteen parasite-free cross cattle were treated with 1% eprinomectin injectable oil formulation at a dose rate of 0.2 mg·kg-1body weight.Six batches of three treated animals(two males and one female) each were selected randomly at 1,3,7,14,21,and 28 days withdrawal after injection and the tissue(muscle,liver,kidney,and fat) samples were collected and analyzed by the above HPLC-FLD method.The results indicated that the residue concentration in muscle(2.1-9.3 ng·g-1) was below the limit(10 ng·g-1) approved by USA and the concentration in liver(29.8-625.1 ng·g-1) was below the limits(4 800,1 500 and 2 000 ng·g-1) recommended by USA,EU,and CAC,respectively.The levels of eprinomectin residues in kidney and fat(4.1-112.5 ng·g-1 and 2.1-96.4 ng·g-1) were less than the limits(300 and 250 ng·g-1) regulated by EU and CAC.The withdrawal periods for all bovine tissues were zero days after the residue concentration-time data were analyzed using a statistical method recommended by Committee for Veterinary Medicinal Products(CVMP) of The European Agency for the Evaluation of Medicinal Products.
What problem does this paper attempt to address?